The RK-1 continuous mixing processor from Readco Kurimoto is suited for testing formulations in continuous processing conditions.
Courtesy Readco
Process equipment manufacturer Readco Kurimoto introduced the RK-1 continuous mixing processor, which incorporates the company's proprietary mixing technology in a compact, tabletop unit. The company states that the unit was developed to help product development professionals test new and existing formulations being processed in batches using a continuous process in a controlled, laboratory environment. Scaled down to process 10 lbs/hr, the RK-1 combines heat transfer, mixing, and shear to process multiple powdered, liquid, and viscous ingredients in a single step, while yielding a high quality, homogeneous product at discharge that meets targeted specifications for moisture, texture, color, uniformity, and other criteria.
The novel RK-1 features twin shaft, co-rotating screws with a one-inch diameter set within a closed barrel to promote the intimate contact among wet and dry materials needed to achieve the desired level of mixing, blending, reacting, crystallization, and/or encapsulation. Suitable for use in research and development laboratories for pharmaceuticals and other products, the versatile RK-1 includes touch-screen controls for setup, monitoring, and real-time adjustments. Other available options include a mobile lift table, electric band heater, feed chute, and all-stainless steel construction.
The RK-1 continuous processors are engineered and manufactured in the company's York, PA headquarters. The lab-size processors operate on 220 volts single-phase and are delivered ready to plug in and operate.
Source: Readco
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.